Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers
Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, controlled Phase I study of CMAB809 administered by
intravenous infusion. This study will characterize the pharmacokinetic, safety and
immunogenicity of CMAB809 versus Trastuzumab(Herceptin) in healthy male subjects after a
single dose.